Global and China Deep Brain Stimulation (DBS) Market Insights, Forecast to 2027

Deep brain stimulation (DBS) is a neurosurgical procedure involving the implantation of a medical device called a neurostimulator (sometimes referred to as a 'brain pacemaker'), which sends electrical impulses, through implanted electrodes, to specific targets in the brain (brain nuclei) for the treatment of movement and neuropsychiatric disorders. DBS in select brain regions has provided therapeutic benefits for otherwise-treatment-resistant disorders such as Parkinson's disease, essential tremor, dystonia, chronic pain, major depression and obsessive–compulsive disorder (OCD). Despite the long history of DBS, its underlying principles and mechanisms are still not clear. DBS directly changes brain activity in a controlled manner, its effects are reversible (unlike those of lesioning techniques), and it is one of only a few neurosurgical methods that allow blinded studies.
Increasing prevalence of neurological disorders is one of the critical factors driving the growth of this market globally. With more than 450 million people worldwide affected by neurological disorders, such as Alzheimer disease, brain injuries, epilepsy, Parkinson’s disease (PD), strokes, peripheral neuropathy, and paralysis, the market for DBS has a positive outlook in the coming years. For instance, PD is a progressive neurological disorder that affects the central nervous system resulting in muscle stiffness and slow movement. Although PD cannot be cured completely with medicines, DBS is preferred as it can be used to improve motor symptoms. Moreover, in cases of neurological injuries that lead to paralysis or disability, DBS can be used to restore movement, reduce tremor and dyskinesia, and improve the quality of life. Furthermore, DBS also helps in improving bladder control, restoring hand grasp, and improving walking in patients. Therefore, the increasing number of neurological disorders will bolster the growth of this market in the coming years.

Market Analysis and Insights: Global and China Deep Brain Stimulation (DBS) Market
This report focuses on global and China Deep Brain Stimulation (DBS) market.
In 2020, the global Deep Brain Stimulation (DBS) market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In China the Deep Brain Stimulation (DBS) market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Deep Brain Stimulation (DBS) Scope and Market Size
Deep Brain Stimulation (DBS) market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Deep Brain Stimulation (DBS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Deep Brain Stimulation (DBS) market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type
Single-channel DBS
Dual-channel DBS

Segment by Application
Parkinson's Disease
Essential Tremor
Dystonia
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Medtronic
Boston Scientific
Abbott
Beijing Pins
SceneRay